Target attainment and pharmacokinetics of cefotaxime in critically ill patients undergoing continuous kidney replacement therapy
André Wieringa, Birgit C. P. Koch(University Medical Center Groningen), Jasper J. Haringman(Isala), Annemieke Dijkstra(Maasstad Ziekenhuis), Gertjan H.J. Wagenvoort(Isala), Peter G. J. ter Horst(Isala), Alan Abdulla(Erasmus MC)
Cited by 3
Related Papers
Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis
|Annals of the Rheumatic Diseases|2004|464
Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study
|The Lancet Respiratory Medicine|2020|306
A randomized controlled trial with an anti‐CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis
|Arthritis & Rheumatism|2006|255
Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis
|Annals of the Rheumatic Diseases|2003|220
Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis
|Arthritis & Rheumatism|2004|155